Technology

Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.

Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.

BenevolentAI’s Innovation Week enables our team to reflect, build and test new ideas and push the boundaries of AI in drug discovery.

BenevolentAI’s CTO, Daniel Neil, discusses the approaches we use to fuel continuous innovation in order to unlock new opportunities and future growth.

Join BenevolentAI's CEO, Joanna Shields, at the Morgan Stanley Putting the Tech in Biotech Conference

Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.